Fill 1 Return To RT

Navigating Copays in Retina Care

Table of Contents

Prior Authorization Burden for Anti-VEGF Therapies

Ella Leung, MD Saira Khanna, MD Michael M. Lai, MD, PhD Charles C. Wykoff, MD, PhD, FASRS, FACS J. Michael Jumper, MD Jill Blim, MS Sabin Dang, MD
RT Hero Placheolder
RT Hero Placheolder

May/June 2026 Supplement | Navigating Copays in Retina Care

Prior Authorization Burden for Anti-VEGF Therapies

The prior authorization process can be costly and time-consuming for patients and retina specialists.

Ella Leung, MD; Saira Khanna, MD; Michael M. Lai, MD, PhD; Charles C. Wykoff, MD, PhD, FASRS, FACS; J. Michael Jumper, MD; Jill Blim, MS; and Sabin Dang, MD

Ella Leung, MD headshot
Saira Khanna, MD headshot
Michael M. Lai, MD, PhD headshot
Charles C. Wykoff, MD, PhD headshot
J. Michael Jumper, MD headshot
Jill Blim, MS headshot
Sabin Dang, MD headshot

Share:

sdfasdf

Ella Leung, MD headshot

Ella Leung, MD

Retina Specialist, Georgia Retina, Atlanta, Georgia
eleung@garetina.com 
Financial disclosure: None 

Saira Khanna, MD headshot

Saira Khanna, MD

Retina Specialist, Retina Consultants, Chicago
Clinical Assistant Professor, Department of Ophthalmology & Visual Sciences, University of Illinois at Chicago College of Medicine
Financial disclosure: None

Michael M. Lai, MD, PhD headshot

Michael M. Lai, MD, PhD

Retina Specialist, Retina Group of Washington, Chevy Chase, MD
mlai@rgw.com 
Financial disclosure: Data Safety Monitoring Board (Genetech); Consultant (Apellis)

Charles C. Wykoff, MD, PhD headshot

Charles C. Wykoff, MD, PhD, FASRS, FACS

Director of Research, Retina Consultants of Texas and the Greater Houston Retina Research Foundation, Houston
Chairman of Research/Clinical Trials Subcommittee, Retina Consultants of America
Deputy Chair of Ophthalmology, Blanton Eye Institute, Houston
Professor of Clinical Ophthalmology, Houston Methodist Hospital, Houston
Editorial Advisory Board Member, Retina Today
charleswykoff@gmail.com 
Financial disclosure: Consultant (4DMT, Abbvie, Adverum, Alcon, Annexon, Apellis, Astellas, Boehringer Ingelheim, Clearside, Curacle, EyePoint, Genentech/Roche, Gyroscope, IACTA, Janssen, Kiora, Kodiak, Nanoscope, NGM, Novartis, Ocular Therapeutix, OcuTerra, ONL, Opthea, Oxular, Perceive Bio, Perfuse, Ray, Recens Medical, Regeneron, Regenxbio, Stealth BioTherapeutics, Thea, Valo); Research Support (4DMT, Adverum, AffaMed, Alexion, Alimera, Alkahest, Annexon, Apellis, Astellas, Bayer, Boehringer Ingelheim, Clearside, Curacle, EyePoint, Genentech/Roche, Ionis, Kodiak, Nanoscope, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, Opthea, Oxular, Perceive Bio, Regeneron, Regenxbio)

J. Michael Jumper, MD headshot

J. Michael Jumper, MD

Retina Specialist, West Coast Retina, San Francisco
Financial disclosure: Clinical Advisory Board (EyeBiotech); Research Support (Abbvie, Atmosphere Gene Therapy Study, Genentech/Roche, OpRegen Stem Cell Study, Regenxbio)

Jill Blim, MS headshot

Jill Blim, MS

Chief Executive Officer, American Society of Retina Specialists, Chicago
Financial disclosure: None

Sabin Dang, MD headshot

Sabin Dang, MD

Retina Specialist, The Retina Institute, St. Louis, Missouri
Financial disclosure: Speaker (Apellis, Bausch + Lomb, EyePoint, Genentech/Roche, Regeneron)